The Next #1 User of Korean Medical Services: The United States

Last updated: April 30, 2026 — with new 2025 data from Korea's Ministry of Health and Welfare

In April 2026, Korea's Ministry of Health and Welfare released its 2025 international patient statistics — and the headline was historic: for the first time since tracking began in 2009, more than 2 million international patients received care in Korea in a single year (2,011,822, up 71.9% from 2024).

The country ranking shifted too. China overtook Japan for #1, Taiwan moved into third, and the United States — third in 2024 — finished fourth. On the surface, that looks like the U.S. lost ground. It didn't. To see why, you have to look past the rankings and into what each country is actually coming to Korea for.

 

 

Source: Korea Ministry of Health and Welfare

 

 

1. Korea Just Crossed 2 Million

A few numbers worth sitting with:

• 2009 (tracking begins): ~60,000 patients
• 2019 (pre-COVID peak): 497,464
• 2020 (COVID): 117,069
• 2025: 2,011,822 — more than 4× the pre-COVID peak

Three years in a row, Korea has roughly doubled its international patient count. Total medical tourism spending hit ₩12.5 trillion (~$9 billion USD) in 2025. For context, Korea's 2023 strategic plan had targeted 700,000 international patients by 2027 — they blew past that in 2024 and nearly tripled it in 2025.

 

 

2. The 2025 Country Ranking — and What It Actually Means

Source: Korea Ministry of Health and Welfare

 

China and Taiwan more than doubled. Both stories are essentially the same story: dermatology. Across all international patients in 2025, 62.9% visited dermatology clinics and another 11.2% went to plastic surgery — over 74% of all visits driven by cosmetic procedures, with 87.7% happening at clinic-level providers rather than hospitals.

So when Taiwan's growth pushed it past the U.S. in the rankings, what really happened was: a single department, in a single tier of providers, attracted a wave of beauty-focused tourists. That's a meaningful story — but it's a different story from what's happening with Americans.

 

 

Source: Korea Ministry of Health and Welfare

 

 

3. The U.S. Story Is Different

In 2025, the U.S. sent 173,363 patients to Korea — up 70.4% and the highest number on record. Canadian patients also hit an all-time high at 23,624. North America delivered its strongest year ever, despite 10–15 hour flights.

But the more interesting story is what American patients came for:

• Dermatology: 44.3%
• Internal Medicine (incl. health checkups): 13.2%
• Plastic Surgery: 9.3%

Compare that to the overall mix (62.9% dermatology, 11.2% plastic surgery). U.S. patients are nearly 19 percentage points less concentrated in dermatology, and substantially more diversified into health checkups and internal medicine. The Ministry called this out directly: U.S. patients "are not concentrated in beauty and cosmetic surgery, but utilize a wide range of medical departments" — language used for no other top-five country.

 

 

4. Why Phase 2 Is Where the Real Story Is

Korean medical tourism is really two stories layered together — and they have very different futures.

Phase 1 (Beauty): Fast-moving, easy to copy

Cosmetic medicine behaves like fashion or beauty products: trends move fast, leadership shifts. Shanghai's large-scale dermatology and plastic surgery centers expanded rapidly during and after COVID — and Chinese visitor volume to Korea hasn't fully matched its pre-pandemic peak as a result. Aesthetic preferences also localize: as Chinese, Japanese, and Taiwanese beauty standards mature, the pull of "Korean beauty" naturally softens.

Phase 1 grew Korea to 2 million. But the moat is shallow. Equipment is purchasable. Techniques diffuse. Competing hubs are already rising.

Phase 2 (Health Checkups & Serious-Illness Treatment): Hard to replicate

Phase 2 is built differently. What Korea offers in comprehensive checkups isn't a building or a machine — it's an operational system refined over decades: half-day full-body screenings combining MRI, endoscopy, CT, lab work, and same-day specialist consultation, delivered at one-fifth to one-tenth of U.S. prices. That kind of efficiency requires integrated IT, standardized protocols, a population that uses preventive care heavily, and a regulatory environment that allows packaged pricing. None of those transfer easily across borders.

The same is true for serious-illness treatment at Korea's tertiary general hospitals. Korea's stomach cancer 5-year survival rate is 77% — compared with roughly 33% in the United States. The gap is structural: Korea's national screening program catches cancers earlier, and high-volume centers accumulate clinical experience that compounds year after year. That's not something a competitor builds in five years.

Note: A "tertiary general hospital" is one of 47 medical institutions designated by the Korean government for advanced and severe treatments such as cancer care.

Why Americans Lead Phase 2

Phase 2 is exactly where U.S. patients are concentrated, and they're already the leaders. According to KHIDI's 2024 Statistical Analysis Report (the most recent year with country-by-country tertiary hospital data published):

• The U.S. sent 17,115 seriously ill patients to Korea's tertiary general hospitals in 2024 — 29% of the total, more than any other country.
• U.S. patients ranked #1 in heart disease cases, #2 in cancer, and #2 in brain disease.
• The U.S. is the only OECD country actively sending seriously ill patients to Korea at meaningful scale.

Japan's strong domestic system limits its Phase 2 demand. China and Taiwan are scaling aesthetic infrastructure, but lack the price-quality gap that drives Phase 2. The U.S. has the worst price-to-care ratio in the developed world combined with the highest awareness of Korea's medical capabilities — and that combination doesn't change in the next decade.

If Americans can easily and confidently access Korean care, Phase 2 will accelerate. And in Phase 2, Korea's lead widens with time, not narrows.

 

 

A Note on the Numbers

Korea publishes international patient data in two stages: April (Ministry of Health and Welfare headline figures) and October–November (KHIDI's full Statistical Analysis Report, with tertiary-hospital and serious-illness breakdowns by country).

This article uses 2025 figures for headline numbers (April 2026 release) and 2024 figures for tertiary-hospital and serious-illness data (the most recent country-level breakdown publicly available). We'll update when KHIDI's 2025 report drops.

Sources:

• Headline 2025 figures: Korea Ministry of Health and Welfare (April 2026)
• Tertiary-hospital and serious-illness breakdowns: KHIDI, 2024 Foreign Patient Statistical Analysis Report (October 2025)
• Historical patient counts (2009–2023): KHIDI Statistical Analysis Reports (medicalkorea.or.kr)
• Korea stomach cancer survival: Korea Central Cancer Registry, Cancer Statistics in Korea, 2022
• U.S. stomach cancer survival: National Cancer Institute SEER program

 

 

About the Author

Donkyo Seo
Co-founder & CEO, Himedi

For the past 9 years, Donkyo has helped international patients navigate Korean healthcare. Himedi is licensed by Korea's Ministry of Health & Welfare (License #A-2016-01-01-2345).